This randomized clinical trial compares the effects of tailored dose-dense adjuvant chemotherapy vs standard adjuvant chemotherapy on recurrence-free survival in women with high-risk early breast cancer.
This study pools patient cohorts from randomized and nonrandomized studies to investigate associations between pembrolizumab therapy and tumor response among patients with advanced melanoma with and without prior ipilimumab therapy.
This phase 2 randomized clinical trial comparing treatment with sargramostim plus ipilimumab, compared to ipilimumab alone in patients with unresectable stage III or IV malanoma, reports longer overall survival and lower toxicity, but no difference in progression-free survival.
Günthard and coauthors report the 2014 recommendations of the International Antiviral Society–USA Panel on antiretroviral treatment of adult human immunodeficiency virus (HIV) infection.
To analyze whether previously reported improvement in disease-free survival with adjuvant gemcitabine therapy translates into improved overall survival, Oettle and coauthors conducted a multicenter, open-label, phase 3 randomized trial to evaluate the efficacy and toxicity of gemcitabine in patients with pancreatic cancer after complete tumor resection.
You currently have no searches saved.